Publication for MS4A1 and BLNK

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MS4A1	membrane spanning 4-domains A1	931			[link]
hsa	BLNK	B cell linker	29760

Pubmed ID	Priority	Text
28860953	0.98	BLNK, MS4A1, EBF1, and FCRL2 were marked as top 5 genes.
	0.97	BLNK, MS4A1, EBF1, and FCRL2) were up-regulated in kidney (GSE22707, GSE22229, GSE14655-INT, GSE14655-IOT) datasets.
21628403	0.98	Blnk, and Btg) and decreased expression of Ms4a1 (CD20), a B-lymphocyte surface antigen reported to be of lower expression in t(12;21)+ than t(12;21)- BCP-ALL cases.
22617684	0.97	MS4A1, and BLNK mRNA measured by real-time PCR in PBMCs of healthy control, HD, and pre-dialysis groups.
	0.76	MS4A1 (B), and BLNK (C) mRNA were measured using real-time PCR.
	0.69	MS4A1, and BLNK mRNA were determined using real-time polymerase chain reaction (PCR).
	0.67	MS4A1, and BLNK mRNA measured by real-time PCR in PBMCs of healthy controls and HD and pre-dialysis patients
25629549	0.95	BLNK, CD22, CD79B, FCER2, FCRL2, ID3, IGKC, IGLL1, MS4A1, MZB1 and TCL1A) belonging to the top-ranked gene lists (Supplementary Figure SI5 online) from the different studies.
	0.88	BLNK, CD22, CD40, CD79B, FCER2, and MS4A1; Figure 4d).
26381030	0.95	CD20 is a 33kD transmembrane phosphoprotein believed to function as an ion channel, thereby allowing the influx of calcium necessary for B cell activation, proliferation and differentiation.
22355402	0.89	CD20+LAIR1- B cell fraction in a subgroup of patients would be linked to an in vivo downregulation of LAIR1 upon B cell activation.
30116248	0.88	BLNK, BTK, CD21, CD40, LYN, MS4A1, and PTPRC (Figure 4).
	0.54	BLNK, BTK, gain-of-function (GOF), and loss-of-function CARD11, CD19, CD21, CD40, CD81, IKKB, KRAS, LYN, MALT1, MS4A1, NEMO, NFKB1, NFKBIA, ORAI1, PI3K, PLCG2, PTPRC, STIM1, and WIPF1 deficiencies.
22102868	0.82	CD20 (MS4A1), CD21 (CR2), CD22, CD79a/b, SYK, LYN, BLK, BLNK, BOB1 (POU2AF1) and PAX5) were identified as active MYC-binding sites (Table S5).
	0.75	CD20 (MS4A1), CD21 (CR2), CD22, PAX5, SYK, LYN, BLK, BLNK, BOB1 (POU2AF1), CD79a/b) as active MYC target genes (Table S5, Figure 1).
	0.61	CD20, CD79a, BLNK, PAX5), as well as for NF-kB associated proteins (A20, CIAP2), which are down-stream components of the B-cell receptor pathway (Figure 5).
	0.53	CD20, BLNK, PAX5, CD79a) was detected by Western blot analysis of protein extracts derived from control siRNA-treated and MYC siRNA-treated BL cell lines.
27708232	0.74	MS4A1 (CD20), CD24, TCL1A and BLNK (Table 2).
22077380	0.67	MS4A1, BLNK, and HLA-DR1B.
27531189	0.61	B cell activation in the CNS following stroke is an important avenue for future research and is potentially achievable in living patients using PET imaging with radiolabelled anti-CD20 antibodies.